F
Ford Motor Company
F has the edge over THRM overall, supported by stronger modeled upside and stronger valuation.
THRM
Gentherm Incorporated
THRM offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
F Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
F's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
THRM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Healthy |
THRM's balance sheet is currently healthy, and its revenue and profitability are stable, but its cash flow is under pressure.
F PE Valuation
F has no meaningful PE right now: it lost money over the past year.
THRM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 10x | $28.79 | — |
| Cheap | 24x | $6.79 | -76% |
| Fair | 36x | $10.21 | -65% |
| Expensive | 62x | $17.38 | -40% |
| Current | 103x | $28.79 | — |
Historical ranges are pointers, not guarantees.
THRM's PE is in its expensive range at 103x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
F Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect F's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
THRM Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for THRM, but weaker profitability. However, they disagree widely on these estimates.
F Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.78 | — |
| Q3 2026 | -$1.97 | -270% |
| Q2 2026 | -$1.87 | -340% |
| Q1 2026 | -$1.55 | -224% |
| Q4 2025 | -$2.06 | -241% |
| Q3 2025 | $1.16 | +32% |
| Q2 2025 | $0.78 | -19% |
| Q1 2025 | $1.25 | +29% |
| Q4 2024 | $1.46 | +35% |
F has swung to a loss: it lost $1.97 per share over the past year, after a profit the year before.
THRM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.82 | +907% |
| Q3 2026 | $0.28 | -72% |
| Q2 2026 | $0.85 | -16% |
| Q1 2026 | $0.73 | -54% |
| Q4 2025 | $0.59 | -71% |
| Q3 2025 | $0.99 | -54% |
| Q2 2025 | $1.01 | -52% |
| Q1 2025 | $1.59 | +9.7% |
| Q4 2024 | $2.06 | +69% |
THRM has the edge over F on earnings quality, reporting a profit while its opponent remains loss making.
F Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $49.5B | -2% |
| Q2 2026 | $48.3B | -3.8% |
| Q1 2026 | $43.3B | +6.4% |
| Q4 2025 | $45.9B | -4.8% |
| Q3 2025 | $50.5B | +9.4% |
| Q2 2025 | $50.2B | +5% |
| Q1 2025 | $40.7B | -5% |
| Q4 2024 | $48.2B | +4.9% |
F's revenue grew through 2023 and has held roughly level since: $49.5B last quarter, down 2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.9% | -0.1 points |
| Q2 2026 | 1.3% | +0.3 points |
| Q1 2026 | 5.4% | +4.6 points |
| Q4 2025 | -25% | -28 points |
| Q3 2025 | 3.1% | +1.2 points |
| Q2 2025 | 1% | -2.9 points |
| Q1 2025 | 0.8% | -2.1 points |
| Q4 2024 | 2.5% | +3.1 points |
F's operating margin was 2.9% last quarter, about level with the same quarter a year ago.
THRM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $405.1M | +4.7% |
| Q2 2026 | $416.2M | +11% |
| Q1 2026 | $393.7M | +11% |
| Q4 2025 | $382.8M | +8.5% |
| Q3 2025 | $386.9M | +4.1% |
| Q2 2025 | $375.1M | -0.2% |
| Q1 2025 | $353.9M | -0.6% |
| Q4 2024 | $352.9M | -3.8% |
THRM has the edge over F on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | -2.6 points |
| Q2 2026 | 2.6% | -3.8 points |
| Q1 2026 | 2.9% | -2 points |
| Q4 2025 | 4.6% | -2.1 points |
| Q3 2025 | 6.2% | -2.5 points |
| Q2 2025 | 6.4% | -2.4 points |
| Q1 2025 | 4.8% | -0.3 points |
| Q4 2024 | 6.7% | -1.9 points |
THRM has the edge over F on profitability, with a higher operating margin.
F Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.1B | -40% |
| Q2 2026 | $2B | -54% |
| Q1 2026 | -$1.1B | -157% |
| Q4 2025 | $1.1B | +108% |
| Q3 2025 | $5.3B | +50% |
| Q2 2025 | $4.2B | +24% |
| Q1 2025 | $1.9B | +$2.6B |
| Q4 2024 | $530M | +169% |
F has the edge over THRM on cash flow, with more consistent year-over-year improvement.
THRM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $25.4M | -45% |
| Q2 2026 | -$1.2M | -103% |
| Q1 2026 | -$10.7M | +$17.5M |
| Q4 2025 | $6.7M | -51% |
| Q3 2025 | $46.5M | +75% |
| Q2 2025 | $36.2M | +104% |
| Q1 2025 | -$28.2M | -$6.6M |
| Q4 2024 | $13.6M | -52% |
THRM still generates free cash flow, though less than at its 2025 peak: $20M over the past year.
F Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.2% | +89M shares |
| 1 year | +0.7% | +28M shares |
| 3 years | +0.6% | +26M shares |
| 5 years | +1% | +40M shares |
| Available history | +1.8% | +72M shares |
F has 4.1B diluted shares, up 0.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $311M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $150M |
F spent $311M buying back its own shares over the past year, up 107% from the year before.
THRM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -382K shares |
| 1 year | -0.2% | -76K shares |
| 3 years | -7.6% | -2.5M shares |
| 5 years | -8.7% | -2.9M shares |
| Available history | -7.9% | -2.6M shares |
THRM has the edge over F on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $10M |
| Q1 2025 | — |
| Q4 2024 | $10M |
| Q3 2024 | $19.9M |
| Q4 2023 | $60M |
| Q3 2023 | $11.1M |
F Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.5x | Net Cash |
| Q2 2026 | -2.1x | Net Cash |
| Q1 2026 | -2.0x | Net Cash |
| Q4 2025 | -3.4x | Net Cash |
| Q3 2025 | -2.4x | Net Cash |
| Q2 2025 | -2.2x | Net Cash |
| Q1 2025 | -1.8x | Net Cash |
| Q4 2024 | -1.8x | Net Cash |
F has the edge over THRM on leverage, with a lower net debt burden relative to earnings.
THRM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.6x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.6x | Very low |
| Q4 2024 | 0.5x | Very low |
THRM's net debt is less than a year of its operating earnings (EBITDA).
F Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.5 | Neutral |
| Stochastic | 19.6 | Oversold |
F's weekly RSI is 41 (neutral) and its Stochastic is 20 (oversold).
THRM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 23.1 | Neutral |
THRM's weekly RSI is 38 (neutral) and its Stochastic is 23 (neutral).
F PE vs Consumer Cyclical Sector
| Metric | F | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
F has no meaningful PE right now: it lost money over the past year.
THRM PE vs Consumer Cyclical Sector
| Metric | THRM | Sector median | Relative |
|---|---|---|---|
| PE | 103x | 18x | 471% above |
| PE % | 96 | 47 | 49 pts above |
THRM is trading at 103x earnings, a 471% premium to the Consumer Cyclical sector's median of 18x.
F Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.2 | 2.5% below |
| 20 week MA | $13.3 | 11% below |
| 50 week MA | $13.4 | 11% below |
| 100 week MA | $12.1 | 2% below |
| 200 week MA | $12.1 | 1.4% below |
F is in a downtrend: it's below all five of its weekly moving averages, and 1.4% below its 200-week average.
THRM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $30.4 | 5.2% below |
| 20 week MA | $35.7 | 19% below |
| 50 week MA | $34.1 | 16% below |
| 100 week MA | $33.4 | 14% below |
| 200 week MA | $43.3 | 33% below |
THRM is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.
F Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.36 | $8.86 | -5.3% |
| 2021 | $8.86 | $20.3 | +129% |
| 2022 | $20.3 | $11.4 | -44% |
| 2023 | $11.4 | $12.2 | +7.3% |
| 2024 | $12.2 | $10.0 | -18% |
| 2025 | $10.0 | $13.3 | +33% |
| 2026 YTD | $13.3 | $11.9 | -11% |
F has the edge over THRM on returns for 2026, with the stronger performance.
THRM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.3 | $66.0 | +49% |
| 2021 | $66.0 | $82.4 | +25% |
| 2022 | $82.4 | $63.8 | -23% |
| 2023 | $63.8 | $52.4 | -18% |
| 2024 | $52.4 | $39.0 | -25% |
| 2025 | $39.0 | $37.2 | -4.7% |
| 2026 YTD | $37.2 | $28.8 | -23% |
THRM has finished four years in a row lower, and it's down 23% so far in 2026.